Idun deal

The La Jolla company entered into a licensing agreement with the Massachusetts Institute of Technology for a portfolio of programmed cell death (apoptosis) technologies covering two roundworm (Caenorhabditis elegans) genes, ced-3 and ced-9, a fruitfly (Drosophila) gene, rpr, and the human homologues to the genes. The deal also covers assay systems to screen cells for apoptosis and to screen compounds that promote or prevent apoptosis.

Idun is developing small molecule therapeutics to treat cancer, inflammation and degenerative diseases. ...